How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

2,657 results for

Quetiapine

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

141. Extended-release quetiapine fumarate (quetiapine XR) monotherapy and quetiapine XR or lithium as add-on to antidepressants in patients with treatment-resistant major depressive disorder. (PubMed)

Extended-release quetiapine fumarate (quetiapine XR) monotherapy and quetiapine XR or lithium as add-on to antidepressants in patients with treatment-resistant major depressive disorder. Patients with treatment-resistant major depressive disorder (MDD) remain a common clinical challenge.This 6-week, randomised, open-label, rater-blinded trial evaluated once-daily extended-release quetiapine fumarate (quetiapine XR; 300 mg/day) as add-on to ongoing antidepressant and quetiapine XR monotherapy (...) (300 mg/day) compared with add-on lithium (0.6-1.2 mmol/L) in patients with treatment-resistant MDD. Primary efficacy measure: change in Montgomery Åsberg Depression Rating Scale (MADRS) total score from randomisation to week 6 with a pre-specified non-inferiority limit of 3 points on the MADRS.At week 6, both add-on quetiapine XR (n=231) and quetiapine XR monotherapy (n=228) were non-inferior to add-on lithium (n=229); least squares means (LSM) differences (97.5% CI) in MADRS total score changes

2013 Journal of Affective Disorders

142. High- v low-dose quetiapine in schizophrenia: meta-analysis

High- v low-dose quetiapine in schizophrenia: meta-analysis High- v low-dose quetiapine in schizophrenia: meta-analysis High- v low-dose quetiapine in schizophrenia: meta-analysis Painuly N CRD summary The review concluded that high-dose quetiapine was not superior to low doses in the acute treatment of schizophrenia, both in terms of efficacy and effectiveness. In light of the absence of an assessment of trial quality and the limited follow-up periods of the included trials, the author's (...) conclusion should be interpreted with a degree of caution. Authors' objectives To compare the effectiveness of high-dose and low-dose quetiapine in the acute treatment of schizophrenia. Searching PubMed, EMBASE, PsycINFO, AMED, CINHAL and Social SciSearch (SSCI) were searched to August 2007; search terms were reported. References lists of obtained articles were also searched. Study selection Double-blind, randomised controlled trials (RCTs) of the acute treatment of schizophrenia with fixed doses

Full Text available with Trip Pro

2010 DARE.

143. Generalised anxiety disorder: quetiapine

Generalised anxiety disorder: quetiapine Gener Generalised anxiety disorder: quetiapine alised anxiety disorder: quetiapine Evidence summary Published: 15 May 2013 nice.org.uk/guidance/esuom12 pathways K Ke ey points from the e y points from the evidence vidence The content of this evidence summary was up-to-date in May 2013. See summaries of product characteristics (SPCs), British national formulary (BNF) or the MHRA or NICE websites for up- to-date information. Summary There is some evidence (...) that quetiapine monotherapy improves the symptoms of generalised anxiety disorder (GAD) compared with placebo, and limited evidence suggests that it is not more effective than antidepressants. Other limited evidence suggests that adding quetiapine to an antidepressant does not improve symptoms in GAD that has not responded to the antidepressant alone. People taking quetiapine are more likely to discontinue treatment because of adverse effects compared with placebo or active treatment. Licencing status

2013 National Institute for Health and Clinical Excellence - Advice

144. Quetiapine withdrawal: a systematic review

Quetiapine withdrawal: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect measures Timing and effect measures

2019 PROSPERO

145. Cochrane review finds quetiapine is equivalent in efficacy to typical antipsychotics and possibly causes fewer side effects

Cochrane review finds quetiapine is equivalent in efficacy to typical antipsychotics and possibly causes fewer side effects Cochrane review finds quetiapine is equivalent in efficacy to typical antipsychotics, but possibly causes fewer side effects Search National Elf Service Search National Elf Service » » » » Cochrane review finds quetiapine is equivalent in efficacy to typical antipsychotics and possibly causes fewer side effects Jul 22 2013 Posted by Antipsychotic medication is the standard (...) potentially jeopardises your mental health. It would seem sensible, then for clinicians to have the best possible understanding of what to expect from an antipsychotic in order to help them achieve the elusive balancing act between efficacy and tolerability. Quetiapine is a widely used atypical antipsychotic – but is it actually any better than the typical antipsychotics (e.g. chlorpromazine and haloperidol)? Fear not – those lovely Cochrane wizards are back with a review to answer that very question

2013 The Mental Elf

146. Effects of once-daily extended release quetiapine fumarate (quetiapine XR) on quality of life and sleep in elderly patients with major depressive disorder. (PubMed)

Effects of once-daily extended release quetiapine fumarate (quetiapine XR) on quality of life and sleep in elderly patients with major depressive disorder. Major depressive disorder (MDD) is frequently associated with reduced quality of life (QoL) and sleep disturbance. We investigated the effects of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy on QoL and sleep in elderly patients with MDD.Prospectively planned analysis of patient-reported data from an 11-week (9 (...) -week randomized; 2-week post-treatment), double-blind, placebo-controlled, Phase III study. Elderly patients (≥66 years; DSM-IV MDD; Hamilton Rating Scale for Depression [HAM-D] total score ≥22, HAM-D Item 1 score ≥2) were randomized to quetiapine XR (flexible dosing 50-300 mg/day) or placebo.MADRS total score change from randomization at Week 9. Patient-reported outcomes: Quality of Life, Enjoyment and Satisfaction Questionnaire Short Form (Q-LES-Q-SF) % of maximum total score (Items 1-14), Q-LES

2013 Journal of Affective Disorders

147. Randomized, double-blind study of the efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in elderly patients with major depressive disorder. (PubMed)

Randomized, double-blind study of the efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in elderly patients with major depressive disorder. This study assessed the efficacy and tolerability of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in elderly patients with major depressive disorder (MDD).An 11-week (9-week randomized; 2-week posttreatment phase), double-blind, placebo-controlled, Phase III study (D1448C00014 (...) ).A total of 53 centers in Argentina, Estonia, Finland, Russia, Ukraine, and the United States.A total of 338 patients (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition diagnosis of MDD, age ≥66 years, Hamilton Rating Scale for Depression [HAM-D] total score ≥22, HAM-D Item 1 [depressed mood] score ≥2) were randomized (mean age: 71.3 years).Patients were randomized to quetiapine XR (n = 166; flexible-dosing 50-300 mg/day) or placebo (n = 172).Primary outcome was Montgomery Åsberg

2013 The American Journal of Geriatric Psychiatry

148. Double-blind, randomized study of extended release quetiapine fumarate (quetiapine XR) monotherapy in older patients with generalized anxiety disorder. (PubMed)

Double-blind, randomized study of extended release quetiapine fumarate (quetiapine XR) monotherapy in older patients with generalized anxiety disorder. The objective of the study was to evaluate once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in older patients with generalized anxiety disorder (GAD).An 11-week (9-week treatment; 2-week posttreatment), randomized, double-blind, placebo-controlled study (D1448C00015) of flexibly-dosed quetiapine XR (50-300 mg/day (...) -A total score.Patients were randomized to quetiapine XR (n = 223) or placebo (n = 227). At week 9, quetiapine XR significantly reduced HAM-A total score versus placebo (least squares mean -14.97 versus -7.21; p < 0.001); symptom improvement with quetiapine XR versus placebo was significant at week 1 (p < 0.001). At week 9, quetiapine XR demonstrated significant benefits over placebo for HAM-A response and remission rates, HAM-A psychic and somatic cluster, MADRS total, CGI-S, Pittsburgh Sleep Quality

2013 International Journal of Geriatric Psychiatry

149. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in patients with generalized anxiety disorder and a history of inadequate treatment response: a randomized, double-blind study. (PubMed)

Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in patients with generalized anxiety disorder and a history of inadequate treatment response: a randomized, double-blind study. For many patients with generalized anxiety disorder (GAD), first-line treatment does not lead to remission. This study investigated the efficacy and tolerability of adjunctive extended-release quetiapine fumarate (quetiapine XR) in patients with GAD and an inadequate response to selective (...) serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs).Patients were randomized to quetiapine XR or placebo adjunctive to SSRI/SNRIs in an 11-week study. The primary endpoint was change from randomization to week 8 in Hamilton Anxiety Rating Scale (HAM-A) total score. Secondary variables were HAM-A psychic/somatic clusters, response, and remission, and Clinical Global Impression–Severity of Illness (CGI-S) score.A total of 409 patients received quetiapine XR (n

2013 Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists

150. Effects of once-daily extended release quetiapine fumarate (quetiapine XR) on quality of life and sleep in elderly patients with major depressive disorder. (PubMed)

Effects of once-daily extended release quetiapine fumarate (quetiapine XR) on quality of life and sleep in elderly patients with major depressive disorder. Major depressive disorder (MDD) is frequently associated with reduced quality of life (QoL) and sleep disturbance. We investigated the effects of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy on QoL and sleep in elderly patients with MDD.Prospectively planned analysis of patient-reported data from an 11-week (9 (...) -week randomized; 2-week post-treatment), double-blind, placebo-controlled, Phase III study. Elderly patients (≥66 years; DSM-IV MDD; Hamilton Rating Scale for Depression [HAM-D] total score ≥22, HAM-D Item 1 score ≥2) were randomized to quetiapine XR (flexible dosing 50-300 mg/day) or placebo.MADRS total score change from randomization at Week 9. Patient-reported outcomes: Quality of Life, Enjoyment and Satisfaction Questionnaire Short Form (Q-LES-Q-SF) % of maximum total score (Items 1-14), Q-LES

2013 Journal of Affective Disorders

151. Randomized, Double-Blind Study of the Efficacy and Tolerability of Extended Release Quetiapine Fumarate (Quetiapine XR) Monotherapy in Elderly Patients with Major Depressive Disorder. (PubMed)

Randomized, Double-Blind Study of the Efficacy and Tolerability of Extended Release Quetiapine Fumarate (Quetiapine XR) Monotherapy in Elderly Patients with Major Depressive Disorder. This study assessed the efficacy and tolerability of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in elderly patients with major depressive disorder (MDD).An 11-week (9-week randomized; 2-week posttreatment phase), double-blind, placebo-controlled, Phase III study (D1448C00014 (...) ).A total of 53 centers in Argentina, Estonia, Finland, Russia, Ukraine, and the United States.A total of 338 patients (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition diagnosis of MDD, age ≥66 years, Hamilton Rating Scale for Depression [HAM-D] total score ≥22, HAM-D Item 1 [depressed mood] score ≥2) were randomized (mean age: 71.3 years).Patients were randomized to quetiapine XR (n = 166; flexible-dosing 50-300 mg/day) or placebo (n = 172).Primary outcome was Montgomery Åsberg

2013 The American Journal of Geriatric Psychiatry

152. Double-blind, randomized study of extended release quetiapine fumarate (quetiapine XR) monotherapy in older patients with generalized anxiety disorder. (PubMed)

Double-blind, randomized study of extended release quetiapine fumarate (quetiapine XR) monotherapy in older patients with generalized anxiety disorder. The objective of the study was to evaluate once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in older patients with generalized anxiety disorder (GAD).An 11-week (9-week treatment; 2-week posttreatment), randomized, double-blind, placebo-controlled study (D1448C00015) of flexibly-dosed quetiapine XR (50-300 mg/day (...) -A total score.Patients were randomized to quetiapine XR (n = 223) or placebo (n = 227). At week 9, quetiapine XR significantly reduced HAM-A total score versus placebo (least squares mean -14.97 versus -7.21; p < 0.001); symptom improvement with quetiapine XR versus placebo was significant at week 1 (p < 0.001). At week 9, quetiapine XR demonstrated significant benefits over placebo for HAM-A response and remission rates, HAM-A psychic and somatic cluster, MADRS total, CGI-S, Pittsburgh Sleep Quality

2013 International Journal of Geriatric Psychiatry

153. Quetiapine better than risperidone for treating depression in people with schizophrenia

Quetiapine better than risperidone for treating depression in people with schizophrenia Quetiapine better than risperidone for treating depression in people with schizophrenia Search National Elf Service Search National Elf Service » » » » Quetiapine better than risperidone for treating depression in people with schizophrenia Jun 27 2011 Posted by Many published guidelines (including the ), recommend second-generation antipsychotics for the treatment of depression in schizophrenia. This study (...) compared a first-generation antipsychotic (perphenazine) with 4 second-generation antipsychotics (olanzapine, quetiapine, risperidone, and ziprasidone) and the impact these drugs had on the symptoms of depression. The authors used data from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) randomised controlled trial, which was conducted between January 2001 and December 2004. Patients with DSM-IV-defined schizophrenia (N = 1,460) were given perphenazine or one of the 4 second

2011 The Mental Elf

154. Quetiapine monotherapy helps people with generalised anxiety disorder, but side effects may limit its use

Quetiapine monotherapy helps people with generalised anxiety disorder, but side effects may limit its use Quetiapine monotherapy helps people with generalised anxiety disorder, but side effects may limit its use Search National Elf Service Search National Elf Service » » » » Quetiapine monotherapy helps people with generalised anxiety disorder, but side effects may limit its use Oct 26 2011 Posted by People with generalised anxiety disorder (GAD) often fail to achieve remission (recovering (...) baseline or weight gain between groups Four second-generation antipsychotic monotherapy studies containing 1383 patients with generalised anxiety disorder indicated that: treatment with 150 mg of quetiapine was more likely to lead to a clinical response (RR = 1.31; 95% CI, 1.20-1.44), remission (RR = 1.44; 95% CI, 1.23-1.68), and a greater decrease in the Hamilton Anxiety Rating Scale score (-3.66; 95% CI, -5.13 to -2.19) than placebo however, an increased risk of all-cause discontinuation (RR = 1.30

2011 The Mental Elf

155. Quetiapine for Delirium Prophylaxis in High-risk Critically Ill Patients

Quetiapine for Delirium Prophylaxis in High-risk Critically Ill Patients Quetiapine for Delirium Prophylaxis in High-risk Critically Ill Patients - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Quetiapine (...) by (Responsible Party): Brian Daley, University of Tennessee Graduate School of Medicine Study Details Study Description Go to Brief Summary: Scheduled, low-dose quetiapine is effective in preventing delirium in high-risk critically ill, trauma/surgical patients. Prophylaxis also reduced ventilator duration and ICU length of stay. Condition or disease Intervention/treatment Phase Psychomotor Agitation Drug: Quetiapine Phase 4 Detailed Description: Objective: To evaluate the efficacy of scheduled quetiapine

2015 Clinical Trials

156. Effects of green tea extracts on the pharmacokinetics of quetiapine in rats. (PubMed)

Effects of green tea extracts on the pharmacokinetics of quetiapine in rats. Quetiapine is an atypical antipsychotic, used clinically in the treatment of schizophrenia, acute mania in bipolar disorders, and bipolar depression in adults. In this study, the effect of green tea extracts (GTE) on the pharmacokinetics of quetiapine (substrate of CYP3A4) was investigated in rats. Male Wistar albino rats received GTE (175 mg/kg) or saline (control) by oral gavage for 7 days before a single (...) intragastric administration of 25 mg/kg quetiapine. Plasma concentrations of quetiapine were measured up to 12 h after its administration by a validated ultraperformance liquid chromatography-tandem mass spectroscopy. Pretreatment with GTE produced significant reductions in the maximum plasma concentration and area under the curve of quetiapine by 45% and 35%, respectively, compared to quetiapine alone. However, GTE did not produce significant change in elimination half-life and oral clearance

Full Text available with Trip Pro

2015 Evidence-based Complementary and Alternative Medicine (eCAM)

157. Histamine H1 receptor occupancy by the new-generation antipsychotics olanzapine and quetiapine: a positron emission tomography study in healthy volunteers. (PubMed)

Histamine H1 receptor occupancy by the new-generation antipsychotics olanzapine and quetiapine: a positron emission tomography study in healthy volunteers. Histamine H1 antagonists have hypnotic, appetite-promoting, and sedative side effects. Most second-generation antipsychotics have potent antagonistic effects on histamine H1 receptor (H1R). Positron emission tomography (PET) can measure the H1R occupancy (H1RO) in vivo, although there are no reports regarding antipsychotics.We studied (...) the H1RO of olanzapine and quetiapine in vivo with respect to their plasma concentrations and subjective drowsiness by performing human PET imaging studies with [(11)C]doxepin, a potent PET ligand of H1R.Six healthy Japanese male volunteers were enrolled. Cross-randomized PET imaging was performed after a single oral administration of olanzapine (2.5 mg), quetiapine (25 mg), or placebo. PET data were analyzed by region of interest and voxel-by-voxel analysis. We concurrently measured plasma drug

2015 Psychopharmacology

158. Cognitive effects of quetiapine XR in patients with euthymic bipolar disorder. (PubMed)

Cognitive effects of quetiapine XR in patients with euthymic bipolar disorder. 24717252 2015 02 09 2015 11 19 1533-712X 34 3 2014 Jun Journal of clinical psychopharmacology J Clin Psychopharmacol Cognitive effects of quetiapine XR in patients with euthymic bipolar disorder. 383-5 10.1097/JCP.0000000000000078 Rakofsky Jeffrey Jay JJ Department of Psychiatry and Behavioral Sciences Emory University School of Medicine Atlanta, GA Jrakofs@emory.edu Department of Psychiatry and Behavioral Sciences (...) Support, Non-U.S. Gov't United States J Clin Psychopharmacol 8109496 0271-0749 0 Antipsychotic Agents 0 Delayed-Action Preparations 0 Dibenzothiazepines 2S3PL1B6UJ Quetiapine Fumarate IM Antipsychotic Agents administration & dosage therapeutic use Bipolar Disorder drug therapy Cognition drug effects Delayed-Action Preparations Dibenzothiazepines administration & dosage therapeutic use Female Follow-Up Studies Humans Male Quetiapine Fumarate Treatment Outcome 2014 4 11 6 0 2014 4 11 6 0 2015 2 11 6 0

2015 Journal of Clinical Psychopharmacology

159. Comparative Study of Aripiprazole, Quetiapine and Ziprasidone in Treatment of First Episode Psychosis: 3-year Follow-up

Comparative Study of Aripiprazole, Quetiapine and Ziprasidone in Treatment of First Episode Psychosis: 3-year Follow-up Comparative Study of Aripiprazole, Quetiapine and Ziprasidone in Treatment of First Episode Psychosis: 3-year Follow-up - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum (...) number of saved studies (100). Please remove one or more studies before adding more. Comparative Study of Aripiprazole, Quetiapine and Ziprasidone in Treatment of First Episode Psychosis: 3-year Follow-up (PAFIP2_3Y) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02526030 Recruitment Status

2015 Clinical Trials

160. Efficacy and Safety of Risperidone and Quetiapine in Adolescents With Bipolar II Disorder Comorbid With Conduct Disorder. (PubMed)

Efficacy and Safety of Risperidone and Quetiapine in Adolescents With Bipolar II Disorder Comorbid With Conduct Disorder. Although a frequent co-occurrence between bipolar disorder (BD) and conduct disorder (CD) in youth has been frequently reported, data about pharmacological management are scarce and focused on BD type I. Second generation antipsychotics are frequently used in clinical practice, but no comparative studies are available. The aim of this exploratory study was to compare (...) efficacy and safety of risperidone and quetiapine in a sample of adolescents presenting a BD type II comorbid with CD. Twenty-two patients diagnosed with a structured interview according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, (male/female ratio, 12/10; mean (SD) age 15.0 (1.4) years) were randomized in 2 treatment groups (quetiapine [n = 12] vs risperidone [n = 10]), treated with flexible doses, and followed up for 12 weeks. Efficacy measures assessed manic symptoms

2015 Journal of Clinical Psychopharmacology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>